Become a member today. It's free.
We will not release or resell your information to third-parties without your permission.
Immune develops next-generation antibodies Immune is a privately held Israeli biopharmaceutical company focused on the development of antibody therapeutics for treating inflammatory diseases and cancer. Its lead product, bertilimumab (previously CAT-213), is licensed for non-ophthalmic indications from the Canadian biotech iCo Therapeutics (and originated at Cambridge Antibody Technology in the UK). Immune also has a technology, NanomAbs, for generating antibody drug conjugates, in preclinical studies. http://www.forexpros.com/analysis/epicept-corporation-merges-with-immune-pharmaceuticals-144694